Clinical trials: Calcitonin Gene-related Peptide
Dental Pain, Pulpitis
Evaluation of Pulpal and Salivary Neuropeptides in Dental Pain
This observational cross-sectional study is designed to evaluate pulpal and salivary levels of Substance P (SP) and Calcitonin Gene-Related Peptide (CGRP) in individuals with and without dental pain.
- Conditions
- Dental Pain, Pulpitis, Pulpal Inflammation, Psychological Stress
- Trial name
- PAIN-SPCGRP (NCT07330024)
- Where
- Turkey (Türkiye)
- Volunteers
- 72 people
- Sponsor
- Kahramanmaras Sutcu Imam University
Hypophosphatemia
FGF-23 Suppressibility by Calcitonin
Introduction: Based on our experience with calcitonin as an FGF-23 suppressive agent in a patient with an FGF-23 producing tumor we hypothesize that calcitonin may be a physiologically important regulator of FGF-23 production and…
- Trial name
- NCT00688077
- Testing
- Calcitonin
- Where
- Netherlands
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Rijnstate Hospital
Episodic Migraine, Chronic Migraine
CGRP Inhibition, Autonomic Function, and Migraine
The purpose of this clinical study is to better understand the function of the autonomic nervous system in patients with migraine. We aim to understand whether the autonomic functions change depending on the migraine status (i.e.
- Trial name
- CGRP-1 (NCT04628429)
- Testing
- Erenumab, Galcanezumab, Fremanezumab
- Where
- Austria
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Trigeminal Neuropathy
Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.
This study is a single center, placebo-controlled, double blind, randomized, phase II pilot to evaluate the efficacy of erenumab-aooe in the management of trigeminal neuropathic pain comparing erenumab-aooe vs Placebo.
- Trial name
- NCT05142228
- Testing
- Erenumab-Aooe
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Maryland, Baltimore
Angina Pectoris, Coronary Heart Disease
A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)
This study will assess the safety of telcagepant in coronary artery disease (CAD) participants with stable angina during exercise treadmill testing and evaluate whether calcitonin gene-related peptide (CGRP) receptor antagonism…
- Conditions
- Angina Pectoris, Coronary Heart Disease, Calcitonin Gene-related Peptide Receptor
- Trial name
- NCT01294709
- Testing
- telcagepant
- Volunteers
- 64 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine Aura, Migraine With Aura
Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide
Calcitonin gene-related peptide (CGRP) is a key neuropeptide in migraine pathophysiology and treatment. This study investigates whether CGRP administration can trigger aura in individuals with a diagnosis of migraine with aura.
- Trial name
- NCT07021859
- Testing
- Calcitonin-gene related peptide (CGRP)
- Where
- Denmark
- Volunteers
- 21 people
- Sponsor
- Danish Headache Center
Osteoporosis, Post-Menopausal
A Study of the Treatment of Postmenopausal Women With Osteoporosis
To compare the effect of treatment with teriparatide with that of salmon calcitonin in postmenopausal women with osteoporosis.
- Trial name
- NCT00543023
- Testing
- teriparatide 20 micrograms/day subcutaneous, salmon calcitonin 100 IU/day subcutaneous
- Where
- 2 sites in China
- Volunteers
- 104 people
- Sponsor
- Eli Lilly and Company
Idiopathic Intracranial Hypertension (IIH)
Eptinezumab for Chronic Headache in Idiopathic Intracranial Hypertension
The goal of this clinical trial is to learn if eptinezumab can reduce headache frequency and headache-related disability in adults with idiopathic intracranial hypertension (IIH) and chronic headache.
- Trial name
- PRIMA (NCT07645833)
- Testing
- Eptinezumab
- Volunteers
- 96 people
- Sponsor
- Rigmor Højland Jensen
Rib Fractures, Pain
Analgesic Effect of Intranasal Calcitonin on Patients With Fractured Ribs
This study, which will be conducted at the emergency room of the Sacré-Cœur hospital, requires the recruitment of 60 subjects and involves some telephone follow-up.
- Trial name
- NCT00444808
- Testing
- Intranasal calcitonin
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- Université de Montréal
Effect of Drug, Migraine Disorders
The Lacosamide's Effect on Calcitonin Gene-related Peptide in Migraine Patients
We assessed serum CGRP concentrations before and after treatment in two hundred episodic migraine patients according to the International Classification of Headache Disorders 3rd edition, aged 10-55 years.
- Trial name
- NCT05632133
- Testing
- Lacosamide 50 MG Oral Tablet, Ibuprofen 400 mg
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Kafrelsheikh University
Migraine
Ultrasound Guided Block of Stellate Ganglion Versus Greater Occipital Nerve in Resistant Migraine and Correlation to Calcitonin Gene Related Peptide
To investigate the efficacy of Ultrasound guided Stellate Ganglion block in chronic resistant migraine patients in comparison to Greater Occipital Nerve Block correlating its effect to serum CGRP level.
- Trial name
- NCT06662461
- Testing
- ultrasound guided Greater occipital nerve block, Ultrasound guided Stellate ganglion block
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Ain Shams University
New Daily Persistent Headache, New Daily Persistent Headache (NDPH)
New Daily Persistent Headache Biomarkers Study
New daily persistent headache is a debilitating syndrome which is seldom researched, poorly understood, and without effective treatments. Chronic migraine is a more common but similarly disabling disorder.
- Trial name
- NDPH (NCT04260087)
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Osteoarthritis
SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study
The purpose of this study is to expose patients with OA to calcitonin and to determine plasma calcitonin levels after administration of 0.6 mg and 0.8 mg oral calcitonin.
- Trial name
- NCT00486369
- Testing
- Oral salmon calcitonin
- Where
- Denmark
- Sponsor
- Nordic Bioscience A/S
Chronic Migraine
Calcitonin Gene-related Peptide Levels in Chronic Migraine
Twenty patients will be enrolled in a 2-site, 7-month, double-blind study conducted to evaluate a reduction in headache days and attacks and calcitonin gene-related peptide (CGRP) levels in saliva following treatment with…
- Trial name
- NCT01071096
- Testing
- OnabotulinumtoxinA, Saline
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Cady, Roger, M.D.
Migraine Disorders
Safety Tolerability and Pharmacokinetics of ALD403
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALD403, a monoclonal antibody, administered by intravenous infusion and subcutaneous injection.
- Trial name
- NCT01579383
- Testing
- ALD403, Sumatriptan
- Where
- Australia
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Alder Biopharmaceuticals, Inc.
Medullary Thyroid Cancer (MTC)
QUILT-3.006 for Recurrent Medullary Thyroid Cancer
Background: GI-6207 is an experimental cancer vaccine made with baker's yeast. The yeast has been modified to help the immune system target a protein called CEA.
- Trial name
- NCT01856920
- Testing
- GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- NantCell, Inc.
Brain Concussion
Tissue Repository and Master Database for Concussion Biomarker and Risk Calculator Development
The purpose of this study is to prospectively collect a comprehensive, multi-modality set of diagnostics on patients who have had a concussion, repeating some of these tests serially over time, so that the investigators may then…
- Trial name
- NCT02519998
- Testing
- Concussion
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Episodic Migraine
Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients
This study is to evaluate the efficacy and safety of AMG334 in adult patients with episodic migraine
- Trial name
- EMPOwER (NCT03333109)
- Testing
- Erenumab
- Where
- 81 sites in Argentina, India and 9 more
- Volunteers
- 900 people
- Sponsor
- Novartis Pharmaceuticals
Migraine, Head Pain
Anti-CGRP Monoclonal Antibody Response After Switching (AMARAS)
Monoclonal antibodies targeting calcitonin gene-related peptide (mAb-CGRP) have shown efficacy and effectiveness in the treatment of episodic and chronic migraine, however, not all patients respond to them.
- Trial name
- AMARAS (NCT05785988)
- Where
- Spain
- Volunteers
- 600 people
- Sponsor
- Hospital Clínico Universitario de Valladolid
Migraine
Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatment for episodic migraine.
- Trial name
- NCT05217927
- Testing
- Rimegepant 75mg daily dosing, Rimegepant 75mg every other day dosing
- Where
- 107 sites in United States, Austria and 8 more
- Volunteers
- 1,415 people
- Sponsor
- Pfizer